In our latest webinar, a number of expert practitioners discussed the latest findings of the use of 2.5% iPAAG (ArthramidVet) and upcoming advances.
EquiManagement has summarised the webinar in their blog below, which covers the latest findings on the use of 2.5% iPAAG (ArthramidVet®) for joint treatment, the mechanism of action, its treatment success rates, timeframe for success, and upcoming research.
Read the full article by EquiManagement HERE
ArthramidVet hosted this discussion with Dr Andrew Watts and Dr Tracy Turner, experts in equine foot health. Our Panelists Dr Andrew Watts (AU): Graduating from University of Queensland in…
Japan Racing Association (JRA) Anti-Doping Statement Regarding 2.5% PAAG Arthramid® Vet. The Japan Central Racing Association Feed and Drug Inspection Supervisory Committee Secretariat Anti-Doping Division, Horse Affairs Department have…
Simon Zahra is a familiar face in the thoroughbred racing game, he grew up in the industry, he’s been training for about 25 years and was also a part of…
